474 related articles for article (PubMed ID: 15002040)
1. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells.
Yang CR; Wang JH; Hsieh SL; Wang SM; Hsu TL; Lin WW
Cell Death Differ; 2004 Jul; 11 Suppl 1():S97-107. PubMed ID: 15002040
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.
Kobayashi K; Takahashi N; Jimi E; Udagawa N; Takami M; Kotake S; Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Morinaga T; Higashio K; Martin TJ; Suda T
J Exp Med; 2000 Jan; 191(2):275-86. PubMed ID: 10637272
[TBL] [Abstract][Full Text] [Related]
3. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase.
Glantschnig H; Fisher JE; Wesolowski G; Rodan GA; Reszka AA
Cell Death Differ; 2003 Oct; 10(10):1165-77. PubMed ID: 14502240
[TBL] [Abstract][Full Text] [Related]
4. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
5. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.
Sankar U; Patel K; Rosol TJ; Ostrowski MC
J Bone Miner Res; 2004 Aug; 19(8):1339-48. PubMed ID: 15231022
[TBL] [Abstract][Full Text] [Related]
6. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression.
Karsdal MA; Hjorth P; Henriksen K; Kirkegaard T; Nielsen KL; Lou H; Delaissé JM; Foged NT
J Biol Chem; 2003 Nov; 278(45):44975-87. PubMed ID: 12933809
[TBL] [Abstract][Full Text] [Related]
8. Yukmijihwang-tang inhibits receptor activator for nuclear Factor-κB ligand-induced osteoclast differentiation.
Shim KS; Ma CJ; Kim DS; Ma JY
J Med Food; 2011 Nov; 14(11):1439-47. PubMed ID: 21883017
[TBL] [Abstract][Full Text] [Related]
9. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function.
Jimi E; Akiyama S; Tsurukai T; Okahashi N; Kobayashi K; Udagawa N; Nishihara T; Takahashi N; Suda T
J Immunol; 1999 Jul; 163(1):434-42. PubMed ID: 10384146
[TBL] [Abstract][Full Text] [Related]
10. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor.
Huber DM; Bendixen AC; Pathrose P; Srivastava S; Dienger KM; Shevde NK; Pike JW
Endocrinology; 2001 Sep; 142(9):3800-8. PubMed ID: 11517156
[TBL] [Abstract][Full Text] [Related]
11. Quercetin triggers apoptosis of lipopolysaccharide (LPS)-induced osteoclasts and inhibits bone resorption in RAW264.7 cells.
Guo C; Hou GQ; Li XD; Xia X; Liu DX; Huang DY; Du SX
Cell Physiol Biochem; 2012; 30(1):123-36. PubMed ID: 22759961
[TBL] [Abstract][Full Text] [Related]
12. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
[TBL] [Abstract][Full Text] [Related]
13. Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling.
Rahman MM; Bhattacharya A; Fernandes G
J Lipid Res; 2006 Aug; 47(8):1739-48. PubMed ID: 16702601
[TBL] [Abstract][Full Text] [Related]
14. Activation of p38 mitogen-activated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor.
Matsumoto M; Sudo T; Maruyama M; Osada H; Tsujimoto M
FEBS Lett; 2000 Dec; 486(1):23-8. PubMed ID: 11108836
[TBL] [Abstract][Full Text] [Related]
15. MKK3/6-p38 MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromal cells.
Rossa C; Ehmann K; Liu M; Patil C; Kirkwood KL
J Interferon Cytokine Res; 2006 Oct; 26(10):719-29. PubMed ID: 17032166
[TBL] [Abstract][Full Text] [Related]
16. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF.
Zauli G; Rimondi E; Nicolin V; Melloni E; Celeghini C; Secchiero P
Blood; 2004 Oct; 104(7):2044-50. PubMed ID: 15213096
[TBL] [Abstract][Full Text] [Related]
17. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages.
Rahman MM; Kukita A; Kukita T; Shobuike T; Nakamura T; Kohashi O
Blood; 2003 May; 101(9):3451-9. PubMed ID: 12511413
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
Nagata N; Kitaura H; Yoshida N; Nakayama K
Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms involved in the enhancement of osteoclast formation by enamel matrix derivative.
Itoh N; Kasai H; Ariyoshi W; Harada E; Yokota M; Nishihara T
J Periodontal Res; 2006 Aug; 41(4):273-9. PubMed ID: 16827720
[TBL] [Abstract][Full Text] [Related]
20. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
Gong W; Dou H; Liu X; Sun L; Hou Y
Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
